Cargando…

Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis

The scientific community still faces the challenge of developing strategies to cure HIV-1. One of these pursued strategies is the development of immunotherapeutic vaccines based on dendritic cells (DCs), pulsed with the virus, that aim to boost HIV-1 specific immune response. We aimed to review DCs-...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelho, Antonio Victor Campos, de Moura, Ronald Rodrigues, Kamada, Anselmo Jiro, da Silva, Ronaldo Celerino, Guimarães, Rafael Lima, Brandão, Lucas André Cavalcanti, de Alencar, Luiz Cláudio Arraes, Crovella, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187785/
https://www.ncbi.nlm.nih.gov/pubmed/27898045
http://dx.doi.org/10.3390/ijms17121985
_version_ 1782486897381081088
author Coelho, Antonio Victor Campos
de Moura, Ronald Rodrigues
Kamada, Anselmo Jiro
da Silva, Ronaldo Celerino
Guimarães, Rafael Lima
Brandão, Lucas André Cavalcanti
de Alencar, Luiz Cláudio Arraes
Crovella, Sergio
author_facet Coelho, Antonio Victor Campos
de Moura, Ronald Rodrigues
Kamada, Anselmo Jiro
da Silva, Ronaldo Celerino
Guimarães, Rafael Lima
Brandão, Lucas André Cavalcanti
de Alencar, Luiz Cláudio Arraes
Crovella, Sergio
author_sort Coelho, Antonio Victor Campos
collection PubMed
description The scientific community still faces the challenge of developing strategies to cure HIV-1. One of these pursued strategies is the development of immunotherapeutic vaccines based on dendritic cells (DCs), pulsed with the virus, that aim to boost HIV-1 specific immune response. We aimed to review DCs-based therapeutic vaccines reports and critically assess evidence to gain insights for the improvement of these strategies. We performed a systematic review, followed by meta-analysis and meta-regression, of clinical trial reports. Twelve studies were selected for meta-analysis. The experimental vaccines had low efficiency, with an overall success rate around 38% (95% confidence interval = 26.7%–51.3%). Protocols differed according to antigen choice, DC culture method, and doses, although multivariate analysis did not show an influence of any of them on overall success rate. The DC-based vaccines elicited at least some immunogenicity, that was sometimes associated with plasmatic viral load transient control. The protocols included both naïve and antiretroviral therapy (ART)-experienced individuals, and used different criteria for assessing vaccine efficacy. Although the vaccines did not work as expected, they are proof of concept that immune responses can be boosted against HIV-1. Protocol standardization and use of auxiliary approaches, such as latent HIV-1 reservoir activation and patient genomics are paramount for fine-tuning future HIV-1 cure strategies.
format Online
Article
Text
id pubmed-5187785
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51877852016-12-30 Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis Coelho, Antonio Victor Campos de Moura, Ronald Rodrigues Kamada, Anselmo Jiro da Silva, Ronaldo Celerino Guimarães, Rafael Lima Brandão, Lucas André Cavalcanti de Alencar, Luiz Cláudio Arraes Crovella, Sergio Int J Mol Sci Review The scientific community still faces the challenge of developing strategies to cure HIV-1. One of these pursued strategies is the development of immunotherapeutic vaccines based on dendritic cells (DCs), pulsed with the virus, that aim to boost HIV-1 specific immune response. We aimed to review DCs-based therapeutic vaccines reports and critically assess evidence to gain insights for the improvement of these strategies. We performed a systematic review, followed by meta-analysis and meta-regression, of clinical trial reports. Twelve studies were selected for meta-analysis. The experimental vaccines had low efficiency, with an overall success rate around 38% (95% confidence interval = 26.7%–51.3%). Protocols differed according to antigen choice, DC culture method, and doses, although multivariate analysis did not show an influence of any of them on overall success rate. The DC-based vaccines elicited at least some immunogenicity, that was sometimes associated with plasmatic viral load transient control. The protocols included both naïve and antiretroviral therapy (ART)-experienced individuals, and used different criteria for assessing vaccine efficacy. Although the vaccines did not work as expected, they are proof of concept that immune responses can be boosted against HIV-1. Protocol standardization and use of auxiliary approaches, such as latent HIV-1 reservoir activation and patient genomics are paramount for fine-tuning future HIV-1 cure strategies. MDPI 2016-11-26 /pmc/articles/PMC5187785/ /pubmed/27898045 http://dx.doi.org/10.3390/ijms17121985 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Coelho, Antonio Victor Campos
de Moura, Ronald Rodrigues
Kamada, Anselmo Jiro
da Silva, Ronaldo Celerino
Guimarães, Rafael Lima
Brandão, Lucas André Cavalcanti
de Alencar, Luiz Cláudio Arraes
Crovella, Sergio
Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title_full Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title_fullStr Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title_full_unstemmed Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title_short Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis
title_sort dendritic cell-based immunotherapies to fight hiv: how far from a success story? a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187785/
https://www.ncbi.nlm.nih.gov/pubmed/27898045
http://dx.doi.org/10.3390/ijms17121985
work_keys_str_mv AT coelhoantoniovictorcampos dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT demouraronaldrodrigues dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT kamadaanselmojiro dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT dasilvaronaldocelerino dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT guimaraesrafaellima dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT brandaolucasandrecavalcanti dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT dealencarluizclaudioarraes dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis
AT crovellasergio dendriticcellbasedimmunotherapiestofighthivhowfarfromasuccessstoryasystematicreviewandmetaanalysis